An Optimized Surfactant-Based PEG-PLCL In Situ Gel Formulation For Enhanced Activity Of Rosuvastatin In Poloxamer-Induced Hyperlipidemic Rats.

Background: Injectable in situ gel (ISG) systems suffer from high initial drug release that may result in toxic effects.

Objective: This work aimed to develop an injectable sustained release rosuvastatin (RSV) ISG formulation with minimum initial drug burst and improved hyperlipidemic efficacy.

Methods: Six formulation factors that affect RSV release after 0.